AbCellera Biologics Expected to Post Q2 Losses with $0.17 EPS

AbCellera Biologics Inc. (ABCL) is expected to report a year-over-year decline in earnings on lower revenues for Q2 2025. The Zacks Consensus Estimate forecasts a quarterly loss of $0.17 per share and revenues of $6.92 million, down 5.5% YoY. The consensus EPS estimate has been revised 4.17% lower over the last 30 days. Investors should look for the direction of estimate revisions and the Zacks Earnings ESP to gauge the potential for a positive or negative earnings surprise.

AbCellera Biologics Inc. (ABCL) is set to report its quarterly earnings for Q2 2025, with analysts expecting a year-over-year decline in earnings due to lower revenues. The Zacks Consensus Estimate forecasts a quarterly loss of $0.17 per share, representing a 30.8% year-over-year change. Revenues are expected to be $6.92 million, down 5.5% from the year-ago quarter [1].

The consensus EPS estimate has been revised 4.17% lower over the last 30 days, indicating a reassessment by analysts of the company's earnings prospects. This revision suggests that analysts are collectively becoming more cautious about ABCL's earnings potential [1].

The Zacks Earnings ESP (Expected Surprise Prediction) for ABCL is currently at +4.00%, indicating that analysts have recently become more bullish on the company's earnings prospects. This positive ESP, combined with a Zacks Rank of #3, suggests that ABCL is likely to beat the consensus EPS estimate [1].

Historically, ABCL has been able to beat consensus EPS estimates in three out of the last four quarters, with the most recent quarter reporting a surprise of +11.76% [1]. This track record of beating estimates may indicate that ABCL has the potential to deliver a positive earnings surprise in its upcoming report.

Investors should pay close attention to the upcoming earnings report and the accompanying earnings call to gauge the company's near-term prospects. While an earnings beat or miss may not be the sole factor influencing ABCL's stock price, a positive surprise could lead to a short-term increase in stock price. Conversely, a miss could result in a decrease in stock price [1].

References:
[1] https://www.nasdaq.com/articles/abcellera-biologics-inc-abcl-expected-beat-earnings-estimates-can-stock-move-higher